2.1
Zanubrutinib (Brukinsa, BeiGene) is indicated for the 'treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy'.
2 Information about zanubrutinib
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for zanubrutinib.
Price
2.3
The list price for zanubrutinib is £4,928.65 for a 120 pack of 80‑mg capsules (excluding VAT, BNF online, accessed May 2025).
2.4
The company has a commercial arrangement. This makes zanubrutinib available to the NHS with a discount. The size of the discount is commercial in confidence.
Carbon Reduction Plan
2.5
For information, the Carbon Reduction Plan for UK carbon emissions is published on the company's webpage on responsible business and sustainability.